Eclipsebio
Next-generation assays. Data-driven analytics. RNA breakthroughs.
Next-generation assays. Data-driven analytics. RNA breakthroughs.
Eclipsebio is a biotechnology company based in the United States, founded in 2017. The company has recently secured a significant $14.00M Series A investment on 15 March 2022 from notable investors including Alexandria Venture Investments, Phoenix Venture Partners, Photon Venture Alpha, and iGlobe. Eclipsebio focuses on accelerating the development of tomorrow's key RNA genomics discoveries and medicines, offering innovative standard and customizable solutions that provide more accurate, reproducible, and usable data for biopharma and academic customers worldwide. Their products aim to identify new RNA regulatory and epigenetic mechanisms, spur insights into mRNA-RNA binding protein and miRNA biology, and map new RNA drug targets to expedite the development of safe and effective RNA medicines. With their slogan "Accelerating the Development of Tomorrow's Key RNA Genomics Discoveries & Medicines," Eclipsebio is positioned as a leading player in the RNA genomics space, catering to the evolving needs of the biopharmaceutical and academic communities.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $14.00M | 4 |
|
15 Mar 2022 |
| Venture Round | $11.95M | - | 10 Sep 2021 |
No recent news or press coverage available for Eclipsebio.
We care about your data, and we'd love to use cookies make your experience better.
